The Duke-UNC Comprehensive Sickle Cell Center is a well-established and vitally important statewide resource. The goals of the Center are to: (1) Foster and carry out basic, translational, and clinical research both locally and in collaboration with other Comprehensive Sickle Cell Centers in order to provide significantly improved treatments and ultimately a cure for sickle cell disease. This application presents 1 inter-center collaborative trial, 2 additional clinical research projects, 1 translational and 3 basic science proposals; (2) Support career development of young investigators in sickle cell disease research by establishing a Scholar program that builds on our excellent record of minority investigator recruitment;(3) Continue to develop state-of-the art patient service materials, help support effective community-based programs, and assist in coordination of evidence-based state-wide activities that benefit all sickle cell patients in North Carolina;and (4) Directly provide clinical care to our 1388 pediatric and adult patients that translates the best current models of care and treatment for sickle cell disease into clinical practice, while offering such patients the opportunity to participate in ongoing research. The Duke-UNC Comprehensive Sickle Cell Center with its 4 components (Administrative, Clinical, Patient Service Cores, and Scholar program) functions as a virtual Center through the scientific leadership and direction of its Director, Dr. Marilyn Telen. Dr Telen reports directly to the Dean of the School of Medicine at Duke and enjoys support from senior leadership at both institutions including Dr. Eugene P. Orringer as UNC Site PI. The research project, core, and clinical service leaders comprise the Internal Advisory Group. Interactions with other Center investigators occur regularly through an ongoing series of conferences, meetings and retreats. An External Advisory Committee is proposed. Outreach is accomplished through community-based clinics, the NC Sickle Cell Syndrome Program, and partnership with governmental agencies. The Center draws both on our strong tradition of sickle cell research and our state-of-the art research and clinical resources at both institutions. Of particular note to this application is our ability to translate science from the bench to the bedside - based both on our expertise in clinical research and our history of successful participation in many multi-center trials.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54HL070769-05S3
Application #
7995576
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Program Officer
Luksenburg, Harvey
Project Start
2003-07-01
Project End
2012-03-31
Budget Start
2007-04-01
Budget End
2012-03-31
Support Year
5
Fiscal Year
2010
Total Cost
$57,672
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Telen, Marilyn J; Afenyi-Annan, Araba; Garrett, Melanie E et al. (2015) Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion 55:1378-87
Rein, Lindsay Am; Sung, Anthony D; Rizzieri, David A (2013) New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. Int J Hematol Oncol 2:
De Castro, Laura M; Zennadi, Rahima; Jonassaint, Jude C et al. (2012) Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin Transl Sci 5:437-44
Thornburg, Courtney D; Calatroni, Agustin; Panepinto, Julie A (2011) Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol 33:251-4
Fitzhugh, Courtney D; Lauder, Naudia; Jonassaint, Jude C et al. (2010) Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol 85:36-40
Thornburg, Courtney D; Calatroni, Agustin; Telen, Marilyn et al. (2010) Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr 156:415-9
Thornburg, Courtney D; Dixon, Natalia; Burgett, Shelly et al. (2009) A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 52:609-15
Afenyi-Annan, Araba; Kail, Melanie; Combs, Martha R et al. (2008) Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 48:917-24
De Castro, Laura M; Jonassaint, Jude C; Graham, Felicia L et al. (2008) Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol 83:19-25
Adam, Soheir; Jonassaint, Jude; Kruger, Hillary et al. (2008) Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med 121:916-21

Showing the most recent 10 out of 28 publications